Back to top
more

McKesson (MCK)

(Delayed Data from NYSE)

$607.51 USD

607.51
2,465,178

+58.20 (10.60%)

Updated Nov 7, 2024 04:00 PM ET

After-Market: $604.00 -3.51 (-0.58%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 22% (54 out of 251)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

The Zacks Analyst Blog Highlights Becton Dickinson, Phibro Animal Health, McKesson, and UnitedHealth Group

by Zacks Equity Research

Becton Dickinson, Phibro Animal Health, McKesson, and UnitedHealth Group are part of top Analyst Blog.

Charles River (CRL) Buys Explora BioLabs to Expand in CRO Space

by Zacks Equity Research

Explora BioLabs' business is likely to complement and expand the Charles River's (CRL) CRADL operation within the broader Insourcing Solutions business.

Alcon's (ALC) Surgical Arm Rebounds, New Launches Aid Growth

by Zacks Equity Research

In Vision Care, Alcon (ALC) continues to see strong demand for PRECISION1 and PRECISION1 for Astigmatism, which are the company's newest contact lenses for the mainstream market.

STERIS (STE) Up 8% Since Q3 Earnings: What's Driving It?

by Zacks Equity Research

Investors are optimistic about STERIS' (STE) robust segmental growth and noteworthy acquisitions in the healthcare and pharmaceutical spaces.

Here's Why You Should Retain Charles River (CRL) Stock For Now

by Zacks Equity Research

Investors are optimistic about Charles River's (CRL) strong segmental growth and notable partnerships.

Henry Schein (HSIC) Hits a New 52-Week High: What's Driving It?

by Zacks Equity Research

Investors are optimistic about Henry Schein (HSIC) owing to favorable dental business trends and a strong solvency position.

Zacks.com featured highlights include The Kroger, NVIDIA, Jones Lang LaSalle, Paychex and McKesson

by Zacks Equity Research

The Kroger, NVIDIA, Jones Lang LaSalle, Paychex and McKesson are part of today's Screen of the Week article.

Edwards Lifesciences' (EW) Global Sales Robust Amid Cost Woes

by Zacks Equity Research

Edwards Lifesciences (EW) is registering robust HemoSphere sales in the United States.

Riya Anand headshot

Bet on These 4 Low-Beta, High-Dividend MedTech Stocks for 2022

by Riya Anand

Stocks like Becton, Dickinson and Company (BDX), Phibro Animal Health (PAHC), McKesson Corporation (MCK) and UnitedHealth Group Inc (UNH) are right picks with strong fundamentals.

Bruker's (BRKR) Buyout to Expand Mass Spectrometry Prospects

by Zacks Equity Research

Bruker's (BRKR) acquisition of IonSense will reach the DART ionization technology to a wider customer base.

Here's Why You Should Invest In Henry Schein (HSIC) Now

by Zacks Equity Research

Investors are optimistic about Henry Schein (HSIC) owing to the favorable dental business trends.

Here's Why You Should Hold on to Chemed (CHE) Stock For Now

by Zacks Equity Research

Investors are optimistic about robust performance by Chemed's (CHE) Roto-Rooter arm.

Here's Why You Should Retain Amedisys (AMED) Stock For Now

by Zacks Equity Research

Investors are optimistic about Amedisys' (AMED) strong segmental performance and strategic buyouts.

Thermo Fisher (TMO) Debuts Raman Spectroscopic Analyzer

by Zacks Equity Research

Thermo Fisher's (TMO) Ramina Process Analyzer allows users to conduct precise in situ Raman measurements in a simple manner with high accuracy.

Walgreens (WBA) Expands Medical Care Offerings in California

by Zacks Equity Research

Walgreens' (WBA) new initiative is intended to reduce care gaps and advance care management by providing access to more affordable and convenient services.

Sweta Killa headshot

5 Dividend Growth Stocks for Safe Income Amid Volatility

by Sweta Killa

The Kroger (KR), NVIDIA (NVDA), Jones Lang LaSalle (JLL), Paychex (PAYX) and McKesson (MCK) could be compelling picks amid market volatility.

Here's Why You Should Retain Cooper Companies (COO) Stock Now

by Zacks Equity Research

Cooper Companies (COO) continues to benefit from strength in its business segments.

Quest Diagnostics (DGX) Inks New Diabetic Retinal Imaging Deal

by Zacks Equity Research

Quest Diagnostics' (DGX) new collaboration with IRIS will enhance access to diabetic retinopathy screening in the United States.

Bruker (BRKR) to Support Biopharma Industries With New Buyout

by Zacks Equity Research

Bruker's (BRKR) recent buyout strengthens the company as a key software and solutions provider for small molecule, biologics and new drug modalities pharma companies.

Why McKesson (MCK) is a Top Growth Stock for the Long-Term

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Here's Why You Should Retain Teleflex (TFX) Stock for Now

by Zacks Equity Research

Investors are optimistic about Teleflex (TFX) on increased UroLift demand and strong vascular business.

Medtronic (MDT) Reports Positive Findings Backing RDN System

by Zacks Equity Research

Medtronic's (MDT) Symplicity Spyral RDN system demonstrated durable and clinically significant reductions in blood pressure at the SPYRAL HTN-ON MED trial.

Medtronic (MDT) Innovations Aid Global Growth, Volume Woe Stays

by Zacks Equity Research

In the neuroscience portfolio, Medtronic (/MDT) is gaining market share in Cranial and Spinal technologies.

Abbott (ABT) Aveir VR Leadless Pacemaker Receives FDA Nod

by Zacks Equity Research

Abbott's (ABT) Aveir VR is a leadless pacemaker designed to treat patients with slow heart rhythms in the United States.

Zimmer Biomet (ZBH) Hurt by China VBP, COVID-Led Staff Shortage

by Zacks Equity Research

Zimmer Biomet (ZBH) expects to face an adverse pricing impact in the first half of 2022, which is being compared to the non-VBP first half of 2021.